Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Other Non-Current Liabilities (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Other Non-Current Liabilities for 16 consecutive years, with $5.8 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 7.58% to $5.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.8 million through Dec 2025, down 7.58% year-over-year, with the annual reading at $5.8 million for FY2025, 7.58% down from the prior year.
  • Other Non-Current Liabilities hit $5.8 million in Q4 2025 for Cumberland Pharmaceuticals, down from $6.0 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $11.3 million in Q1 2022 to a low of $5.8 million in Q4 2025.
  • Historically, Other Non-Current Liabilities has averaged $7.3 million across 5 years, with a median of $6.8 million in 2023.
  • Biggest five-year swings in Other Non-Current Liabilities: soared 44.56% in 2022 and later crashed 37.38% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $7.5 million in 2021, then rose by 1.28% to $7.6 million in 2022, then fell by 14.92% to $6.5 million in 2023, then decreased by 2.38% to $6.3 million in 2024, then dropped by 7.58% to $5.8 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for CPIX at $5.8 million in Q4 2025, $6.0 million in Q3 2025, and $6.3 million in Q2 2025.